Legacy CG’s Colgate-Palmolive CL Stock Holding History

Legacy CG’s Portfolio CL Stock Details CL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-123	Closed	-$10K	–	59
2022 Q2	$10K	Buy	+123	New	+$9.62K	0.01%	100

Other funds holding CL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Third Point New York $2.08B AUM 27.04% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Legacy CG's CL Position: Q3 2022 in Review

Legacy CG sold out of Colgate-Palmolive (CL) in Q3 2022, closing a stake of 123 shares — an estimated $10K sold.

Legacy CG first reported a position in CL in Q2 2022 and held it in 1 quarter. The position peaked at $10K in Q2 2022. 1,614 funds tracked by Wall St. Rank hold CL as of Q3 2022.

Legacy CG reported no remaining Colgate-Palmolive position as of Q3 2022 after selling out during the quarter.
Legacy CG sold 123 Colgate-Palmolive shares in Q3 2022, an estimated $10K.
Legacy CG first reported a position in Colgate-Palmolive in Q2 2022 and held it in 1 quarter.
Legacy CG's Colgate-Palmolive position peaked at $10K in Q2 2022.
1,614 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q3 2022.

Based on Legacy CG's 13F filing for Q3 2022, filed 4 Nov 2022.